In a randomized trial enrolling 354 patients with heterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy, treatment with the cholesteryl ester transfer protein inhibitor obicetrapib was well tolerated and significantly lowered low-density lipoprotein cholesterol by 36.3% as compared to placebo.
- Stephen J. Nicholls
- Adam J. Nelson
- Michael H. Davidson
